Develop target-specific antibody using oligosaccharide-oligonucleotide conjugates.

About

The invention relates to a method of directed evolution of a large library of carbohydrate-oligonucleotide conjugates, and then a therapeutically-useful monoclonal antibody is used to bind those members of the library which best resemble it's native epitope. Through amplification or diversification of the best binders from the first library, the best epitope mimics are selected from subsequent library generations to provide improved binders.

Key Benefits

•A novel method to generate carbohydrate-oligonucleotide conjugates to produce vaccine •High throughput library screening by utilising a “reverse immunology” approach •A successful strategy for biotech/pharmaceuticals based on exhaustive antigen epitope space

Applications

Though this invention can be used to design vaccines against HIV, it can also be used to discover vaccines against any other diseases for which therapeutically useful antibodies are known to bind to a carbohydrate structure, cancer antigens, for instance, RAV12. Moreover, this invention also enables rapid discovery of oligosaccharide-oligonucleotide conjugates which could specifically disrupt the binding of any know glycoprotein-glycoprotein or proteinglycoprotein interaction in which the binding involves the carbohydrates

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations